Navigation Links
Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
Date:1/25/2008

://www.clinicaltrials.gov (search for Catalyst).

Patrick J. McEnany, Chief Executive Officer of Catalyst, commented: "We are very pleased to announce the start of active enrollment in our study of CPP-109 as a potential treatment for cocaine addiction. We expect to add more clinical trial sites to the 10 previously disclosed in order to complete the trial as soon as possible. We anticipate initial top-line results from this trial to be available by year-end."

Douglas Winship, Catalyst's Vice President of Regulatory Operations, stated: "Vigabatrin has previously shown the potential to be a safe and effective non-addictive drug treatment for cocaine and methamphetamine addiction in a Phase II double-blind, placebo-controlled trial and two pilot studies conducted in Mexico. We are excited to now evaluate the therapeutic benefit of CPP-109 in cocaine-addicted patients enrolled in a large, double- blind, placebo-controlled trial conducted in the U.S. under our sponsorship. There are currently no prescription drugs approved for the treatment of this population. As a result, drug therapies are desperately needed which can improve abstinence achievement rates of behavioral therapy administered by addiction treatment specialists, and reduce recidivism. We have worked diligently with regulatory authorities and the independent institutional review boards at each of the clinical sites where our trial will be conducted to be able to finalize and implement our protocol for this trial."

On December 7, 2007, Catalyst announced positive initial top-line results from a 103-patient, investigator-initiated Phase II double-blind, placebo- controlled trial, in which vigabatrin met its primary efficacy endpoint of abstinence during the last weeks of treatment for cocaine addiction. Additional results of this study will be reported when they become available.

About CPP-109

CPP-109 works by inhibiting an enzyme that normally breaks down gamma aminobuty
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
4. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... LAKEWOOD, Colo. , Dec. 15, 2014  The Government of ... the collaboration of AABB, Global Blood Fund (GBF) and Terumo BCT ... Africa , as well as provide long-term health system capacity ... Key Facts: , The Ghanaian Ebola Readiness and Resilience ... Ghana,s preparations for the possible arrival of ...
(Date:12/13/2014)... , Dec. 11, 2014 Research and ... the addition of the "Drug Injection Devices ... http://photos.prnewswire.com/prnh/20130307/600769 ... of an expanding list of health conditions, drug ... that simplify the administration process and increase the ...
(Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
Breaking Medicine Technology:Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... The " Global Endoscopy Market by Product, ... and studies the major market drivers, restraints, and opportunities in Americas, ... Browse market data tables and in-depth TOC of   ... & Technology (2011- 2016) " ...
... 2012 Oncos Therapeutics today announced the successful ... oncolytic adenovirus suggested as a potential new treatment for many ... the safety assessment part of the study. " ... r thern Europe to start a clinical study ...
Cached Medicine Technology:MarketsandMarkets: Global Endoscopy Market worth $9.7 Billion by 2016 2MarketsandMarkets: Global Endoscopy Market worth $9.7 Billion by 2016 3Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2
(Date:12/17/2014)... San Francisco, CA (PRWEB) December 17, 2014 ... the Stanford Center for Longevity, today, in reaction to a ... the emerging science of brain training and derogated the efficacy ... said that they agreed with the parts of the center’s ... however, they believed the center had also overstated its case, ...
(Date:12/17/2014)... 15, 2014 (HealthDay News) -- As gas prices rose ... a new study suggests. In times of gas ... those riders are inexperienced, the researchers explained. They ... which has the highest number of motorcycle registrations in ... motorcyclist deaths. The analysis revealed a strong association ...
(Date:12/17/2014)... By Alan Mozes ... -- With the holiday party season fast approaching, a new ... and make DUI arrests have fewer drunk drivers on their ... driving laws more vigilantly are better able to deter inebriated ... "Hardly any new laws are being passed regarding drinking ...
(Date:12/15/2014)... 15, 2014 Veretekk.com, Inc. announced today ... Avenue. JM Ocean Avenue has secured exclusive benefit ... automated marketing system. JM Ocean Avenue is a ... of Ocean Avenue and JM International, with partial ownership ... per year company. , “After nearly 2 decades of ...
(Date:12/15/2014)... Boston, MA (PRWEB) December 15, 2014 ... health management solutions, announced today that it has ... for Quality Assurance (NCQA) for its Disease Management ... obstructive pulmonary disease (COPD), coronary heart disease and ... accreditation from NCQA for Health Dialog’s Disease Management ...
Breaking Medicine News(10 mins):Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2
... patients who present with advanced colorectal cancer that has spread to ... primary tumor in the colon. Researchers from Memorial Sloan-Kettering Cancer Center ... Oncology Annual Meeting. , ... population with metastatic disease that cannot be cured by surgery, undergoing ...
... May 30 Wyeth Pharmaceuticals, a division of Wyeth ... The American Society of Clinical Oncology (ASCO) Cancer Foundation ... provide patients with important health information and conduct physician ... the 45th Annual Meeting of the American Society of ...
... FRIDAY, May 29 (HealthDay News) -- Animals -- carnivores ... not necessarily develop bigger brains, say two biologists whose ... many evolutionists. , In a report published online ... Academy of Sciences Early Edition, John Finarelli of ...
... failure represents the most common reason for hospitalisation in ... the first 24 hours after admission in around 50% ... associated with a more than 50% mortality and rehospitalisation ... from the Cardiology Department of the University of Brescia, ...
... have been recently described in Heart Failure (HF) syndrome ... of acute decompensation. Biomarkers are used to diagnose disease ... individuals. , Speaking at a press conference at Heart ... for the European Society of Cardiology, presented these new ...
... of heart failure can be remotely assessed, now provide ... according to Professor John Cleland from the University of ... the management of heart failure is complex but most ... condition.2 "Unfortunately," he added, "the resources required to offer ...
Cached Medicine News:Health News:Surgery not necessary for most late-stage colorectal cancers 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 3Health News:Biologists Question Animal Brain Size Theory 2Health News:Better treatment selection and improved therapies -- key to improving prognosis in acute HF 2Health News:Novel biomarkers in heart failure 2Health News:Individualized treatment for heart failure is rarely available outside hospital 2
... Stainless steel workbench top with ... adjustable from 25"-34". Available in ... Accessories include shelves, drawers, light ... is an expert in custom ...
... is configured specifically for pharmaceutical powder ... Panels are precision-joined to create ultra-smooth ... down and disinfect. One-inch radius corners ... creates strong, rigid surface without external ...
... Cleanroom-grade vinyl curtains or parting ... steel support frame to form ... that meets cleanliness to Class ... filter/fan units, lights, and ionizers ...
Inquire...
Medicine Products: